Ann: Release of ordinary shares from escrow, page-9

Firstly, its Phase 3 trials, not stage 3.

And secondly, CHM are looking to progress the drug through a fast track pathway, just the same was as all CarT drugs have been processed for approval to date. So no phase 3 trial will be required. Just a phase 2b trial, which will be well within the capability of a drug discovery Biotech.

To take this further, as drug approval is within reach in the medium term, revenue and market cap growth follows. All of this minimises share holder dilution as the drug is expanded into other cancers, and new drugs are developed and the pipeline developed.

There is no SOC for GBM. GBM is a very aggressive cancer, with most patients not progressing beyond 6 month from diagnosis. CHM has had its phase 1 trial running from Sept last year. There have been no adverse safety events reported so far. At the completion of this phase 1 trial, CHM will be quickly progressing to a phase 2b trial, with drug approval expected at the completion of that trial, if supported by statically significant data.

The market cap of CHM, is well below its peers in the CarT field. The very low SOI means huge potential for share holders.

An update on the Phase 1 trial is expected in the Sept quarter.